Acarbose

Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM) . Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin[1][2][3].

Product Specifications

CAS Number

[56180-94-0]

Product Name Alternative

BAY g 5421

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Glycosidase

Type

Natural Products

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Acarbose.html

Concentration

10mM

Purity

99.97

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

OC[C@H]([C@]1(O[C@@H]2[C@H](O)[C@@H](O)[C@@H]([C@H](O2)C)N[C@]3(C=C(CO)[C@H]([C@@H]([C@H]3O)O)O)[H])[H])O[C@@H]([C@@H]([C@H]1O)O)O[C@@]([H])([C@@H]([C@H](C=O)O)O)[C@@H](CO)O

Molecular Formula

C25H43NO18

Molecular Weight

645.60

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhang Q, et al. Acarbose Reduces Blood Glucose by Activating miR-10a-5p and miR-664 in Diabetic Rats. PLoS One. 2013 Nov 18;8 (11) :e79697.|[2]Chan KC, et al. Pleiotropic effects of acarbose on atherosclerosis development in rabbits are mediated via upregulating AMPK signals. Sci Rep. 2016 Dec 7;6:3864|[3]Hanefeld M, et al. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits [published correction appears in Expert Rev Cardiovasc Ther. 2009 Mar;7 (3) :330]. Expert Rev Cardiovasc Ther. 2008;6 (2) :153-163.|[4]Yee HS, et al. A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy. 1996;16 (5) :792-805.|[5]Oki T, et al. Evaluation of alpha-glucosidase inhibition by using an immobilized assay system. Biol Pharm Bull. 2000;23 (9) :1084-1087.